Key result
Flecainide depressed anterograde and retrograde conduction of the accessory pathway and terminated circus movement tachycardia in 8 of 9 patients with Wolff-Parkinson-White syndrome.
Why the study?
Does flecainide alter the electrophysiological properties of accessory pathways in patients with Wolff-Parkinson-White syndrome?
Observational (n=12)
Does flecainide alter the electrophysiological properties of accessory pathways in patients with Wolff-Parkinson-White syndrome?
Flecainide depresses conduction in accessory pathways and may be beneficial for treating paroxysmal supraventricular tachycardias in patients with Wolff-Parkinson-White syndrome.
No takes yet. Share an insight, caveat, or question.
May support flecainide in WPW tachycardia; case report leaves open need for controlled confirmation.
Neuß et al. (1983) conducted an observational in Wolff-Parkinson-White syndrome (n=12). Flecainide was evaluated on Electrophysiological properties of the accessory pathway, initiation/termination of circus movement tachycardias, and ventricular response during induced atrial fibrillation. Flecainide depressed anterograde and retrograde conduction of the accessory pathway and terminated circus movement tachycardia in 8 of 9 patients with Wolff-Parkinson-White syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: